SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders

N Amruta, WH Chastain, M Paz, RJ Solch… - Cytokine & growth factor …, 2021 - Elsevier
SARS-CoV-2 is a novel coronavirus that severely affects the respiratory system, is the cause
of the COVID-19 pandemic, and is projected to result in the deaths of 2 million people …

Potential therapeutic options for COVID-19: current status, challenges, and future perspectives

C Sarkar, M Mondal, M Torequl Islam… - Frontiers in …, 2020 - frontiersin.org
The COVID-19 pandemic represents an unprecedented challenge for the researchers to
offer safe, tolerable, and effective treatment strategies for its causative agent known as …

[HTML][HTML] Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

AE Koshak, EA Koshak, AF Mobeireek… - … Therapies in Medicine, 2021 - Elsevier
Abstract Background Effective treatment for Coronavirus Disease-2019 (COVID-19) is under
intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and …

COVID-19 pathogenesis and clinical manifestations

RAH Acosta, ZE Garrigos, JR Marcelin… - Infectious Disease …, 2022 - id.theclinics.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the
Betacoronavirus genus (which also includes SARS 1 and Middle East respiratory syndrome …

Target organ toxicity

PK Gupta, PK Gupta - Problem Solving Questions in Toxicology: A Study …, 2020 - Springer
Several target organs such as liver, kidney, lungs, heart, ocular and visual apparatus, skin,
reproductive organ, immune system, endocrine systems, etc. play an important role for …

Pathogenesis‐directed therapy of 2019 novel coronavirus disease

CW Stratton, YW Tang, H Lu - Journal of medical virology, 2021 - Wiley Online Library
The 2019 novel coronavirus disease (COVID‐19) now is considered a global public health
emergency. One of the unprecedented challenges is defining the optimal therapy for those …

Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery

Y Li, G Hou, H Zhou, Y Wang, HM Tun, A Zhu… - Signal transduction and …, 2021 - nature.com
Disease progression prediction and therapeutic drug target discovery for Coronavirus
disease 2019 (COVID-19) are particularly important, as there is still no effective strategy for …

Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study

A Jorge, KM D'Silva, A Cohen, ZS Wallace… - The Lancet …, 2021 - thelancet.com
Background As the COVID-19 pandemic continues worldwide, severe COVID-19 outcomes
remain a major concern for patients with rheumatic and musculoskeletal diseases. We …

[HTML][HTML] Review of burden, clinical definitions, and management of COVID-19 cases

L McArthur, D Sakthivel, R Ataide, F Chan… - The American journal …, 2020 - ncbi.nlm.nih.gov
Our understanding of SARS-CoV-2, the virus responsible for coronavirus disease 2019
(COVID-19), its clinical manifestations, and treatment options continues to evolve at an …

Clinical characteristics, treatment, and outcomes of critically ill patients with COVID-19: a scoping review

C Huang, J Soleimani, S Herasevich, Y Pinevich… - Mayo Clinic …, 2021 - Elsevier
A growing number of studies on coronavirus disease 2019 (COVID-19) are becoming
available, but a synthesis of available data focusing on the critically ill population has not …